Atea Pharmaceuticals, Inc.
A clinical-stage biopharma developing oral antiviral therapies for viruses like Hepatitis C.
AVIR | NDAQ
Overview
Corporate Details
- ISIN(s):
- US04683R1068
- LEI:
- Country:
- United States of America
- Address:
- 225 FRANKLIN STREET, 2110 BOSTON
- Website:
- https://ateapharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of oral direct-acting antiviral therapies. The company leverages its deep expertise in virology, medicinal chemistry, and biology to develop novel treatments for serious viral diseases, with a particular focus on those caused by single-stranded RNA (ssRNA) viruses. Atea's primary development program is a global Phase 3 trial for its oral regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The company aims to address unmet medical needs and transform patient care with innovative, orally-available antiviral agents.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Atea Pharmaceuticals, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Atea Pharmaceuticals, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Atea Pharmaceuticals, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
